News

Deal Announcements

Aduro BioTech Sees Series B Venture Capital

Thursday, April 21, 2011 5:36:00 AM PDT | VentureDeal Staff
   Berkeley, California  --  Biotechnology company Aduro BioTech has secured $19.25 million in its second round of venture capital investment, according to a company statement.

Aduro is developing therapeutic and prophylactic vaccines for cancer and infectious diseases.

The Morningside Group participated in the round along with other unnamed investors.

The company said it would use the funding to advance its lead pancreatic cancer vaccine into Phase 2 clinical trial.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1